Bridge Biotherapeutics to Showcase BBT-877 at J.P. Morgan Conference

Bridge Biotherapeutics, Inc., a clinical-stage biotech company based in South Korea and the U.S., has announced that its Founder and CEO, James Jungkue Lee, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025. The presentation will take place in the Georgian Room (Mezzanine Level) at The Westin St. Francis in San Francisco, California, from 9:45 to 10:25 a.m. PST.

During the conference, Bridge Biotherapeutics will discuss its major R&D projects, including BBT-877, a novel drug candidate for idiopathic pulmonary fibrosis (IPF). BBT-877 is an autotaxin inhibitor that has shown promising results in clinical trials, with top-line data expected in April 2025. The company is actively seeking business development opportunities for further development and commercialization of BBT-877, as well as other initiatives.



The J.P. Morgan Healthcare Conference is one of the largest and most prestigious healthcare investment conferences in the world, bringing together leading industry executives, investors, and analysts. Bridge Biotherapeutics' presentation at the conference is an excellent opportunity for the company to showcase its innovative drug candidates and engage with potential partners and investors.

In addition to the presentation, Bridge Biotherapeutics plans to meet with potential partners and investors during the conference to discuss technology transfer opportunities for BBT-877 and other initiatives. The company has already signed confidentiality disclosure agreements (CDAs) with more than half of the top 10 global pharmaceutical firms and is in ongoing talks regarding the clinical development and future plans for BBT-877.

The interest from multinational pharmaceutical companies in BBT-877 reflects the significant unmet medical need in the IPF sector, as well as the potential market opportunities for a novel drug with a unique mechanism of action. If BBT-877 demonstrates efficacy and safety in clinical trials, it could become a valuable addition to the IPF treatment landscape, potentially improving the quality of life and survival rates for patients.

In conclusion, Bridge Biotherapeutics' presentation at the 43rd Annual J.P. Morgan Healthcare Conference is an important milestone for the company, as it provides an opportunity to showcase its innovative drug candidates and engage with potential partners and investors. The company's focus on BBT-877, a novel autotaxin inhibitor for IPF, highlights its commitment to addressing unmet medical needs and exploring market opportunities in the fibrotic diseases space.